Joinn Labs prices IPO high in scorching market

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
22 Feb 2021

Joinn Laboratories has sealed its HK$6.54bn ($843.8m) listing at the top of the price range, tapping into Hong Kong’s IPO market as demand hits fever pitch, according to a source familiar with the matter.

The Mainland China-listed issuer – one of the first to hit the equities market after the Chinese New Year break – is a non-clinical contract research organisation (CRO) that assesses drug safety. It raised funds for the expansion of its facilities and services.

Listing sponsor CLSA and global co-ordinators ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial